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Abstract
Introduction: Statins and β1-adrenergic antagonists are well established in car-
diovascular events therapy and prevention. The previous study showed that
statins might impact on β-adrenergic signalling and blood pressure in a dose-
dependent manner. The aim of the study was to evaluate the impact of 4-week
administration of simvastatin given at different doses on the heart rate and
blood pressure after injection of metoprolol in rats.
Material and methods: The experiments were performed in normocholestero-
laemic and normotensive Wistar rats. Rats received simvastatin in doses of 1,
10 and 20 mg/kg body weight (bw) for 4 weeks. The control group received 0.2%
methylcellulose. For the further estimation of the heart rate and blood pres-
sure, metoprolol at 5 mg/kg bw or 0.9% NaCl was injected intraperitoneally.
Results: Simvastatin at doses of 1, 10 and 20 mg/kg bw did not influence the
heart rate or blood pressure as compared to the control group. Metoprolol injec-
tion statistically significantly decreased the heart rate (439.29 ±14.03 min–1 vs.
374.41 ±13.32 min–1; p < 0.05). In rats receiving simvastatin during the 4-week
period after metoprolol injection, heart rate and blood pressure (mean, systolic,
diastolic) were similar as compared to the group receiving metoprolol alone.
Conclusions: Simvastatin administration during a 4-week period in different 
doses did not influence the heart rate or blood pressure after metoprolol injection
in normocholesterolaemic and normotensive rats.
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Introduction
Nowadays 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) inhibitors are
the most important drugs used in the primary and secondary prevention
of cardiovascular events. Their beneficial activity is dependent on limiting
cholesterol synthesis; therefore current guidelines recommend aggressive
cholesterol lowering with statins. Dose-dependent side effects of statins
involving myopathy and alteration of cell membrane are observed, as well
[1, 2]. On the other hand, cholesterol-independent pleiotropic effects of
statins have been reported [3]. In some cases, to obtain target low-den-
sity lipoproteins (LDL)-C, statins are co-administered with other lipid-low-
ering agents [4]. From a practical viewpoint, monotherapy with HMG-CoA
inhibitors is applied; the statin dosage used by patients might be enlarged,
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Copyright © 2012 Termedia & Banachhowever. In therapy, statins are often applied with
β1-blockers such as metoprolol. In the previous
study it was shown that simvastatin influenced the
heart rate and blood pressure after metoprolol
administration [5]. Mülhäuser et al. showed that
atorvastatin desensitized β1-adrenergic signalling
by reducing isoprenylation of G-protein [6]. This
interaction was dependent on both the drug con-
centration and drug administration period. In our
previous study simvastatin after 2 weeks of admin-
istration to normocholesterolaemic and normoten-
sive rats did not influence the heart rate or blood
pressure after bolus injection of metoprolol [7, 8]. 
The aim of the study was to evaluate the influ-
ence of bolus injection of metoprolol after 4-week
administration of simvastatin given at different dos-
es on the heart rate and blood pressure. 
Material and methods
Animals
The study was approved by the Ethics Commit-
tee of the Medical University of Lodz (Poland) –
43/ŁB300-Az/2006. The experiments were per-
formed in 51 8-11-week-old anaesthetized Wistar
rats, outbred males. A several-day adaptation peri-
od was scheduled prior to the beginning of the
experiment. After the adaptation period, animals
were divided into 8 groups receiving: 1) 0.2%
methylcellulose, intragastrically (ig); 2) 0.2% methyl-
cellulose (ig) and metoprolol at 5 mg/kg body
wieght (bw) intraperitoneally (ip); 3) simvastatin at
1 mg/kg bw (ig); 4) simvastatin at 10 mg/kg bw (ig);
5) simvastatin at 20 mg/kg bw (ig); 6) simvastatin
at 1 mg/kg bw (ig) + metoprolol at 5 mg/kg bw (ip);
7) simvastatin at 10 mg/kg bw (ig) + metoprolol at
5 mg/kg bw (ip); 8) simvastatin at 20 mg/kg bw (ig)
+ metoprolol at 5 mg/kg bw (ip). Simvastatin (Pol-
farmex, Poland series no. KY-SI-M20030102) or
placebo (0.2% methylcellulose) were given ig over
a 4-week period. Rats had free access to standard
diet (granulated mix “LSK”) and water. After admin-
istration of drugs or vehicle, heart rate and haemo-
dynamic parameters were measured. The surgery
was performed 24 h after administration of the last
drug dose and 10 h after the last feed supply. For
further surgical procedures, anaesthesia was initi-
ated by an ip dose of pentobarbital sodium at 60
mg/kg bw. The anaesthesia was maintained by
intraperitoneal bolus injections of pentobarbital
sodium at 10 mg/kg bw, as needed. For the meas-
urement of heart rate and blood pressure, catheters
were implanted into the right carotid artery. The
signals were provided by an Isotec pressure trans-
ducer connected to a direct current bridge amplifi-
er (both Hugo Sachs Elektronik). After the haemo-
dynamic stabilization period (about 15 min), an
intraperitoneal single injection of metoprolol at 
5 mg/kg bw or 0.9% NaCl (2 ml/100 g bw) was
administered. After heart rate and blood pressure
assessment, 0.25 ml of blood samples were taken
for further lipid profile examination. Surgical pro-
cedures, heart rate and blood pressure recording
were provided as described previously [7, 8]. The
results of metoprolol injection were given as the
absolute differences from the baseline of heart rate
and as percent of change from the baseline. 
Statistical analysis
All data are presented as means ± SD (standard
deviation). Statistical comparisons between base-
line conditions and metoprolol injection were done
by paired Student's t-test. Comparisons among
groups were performed using ANOVA. Post-hoc
comparisons were performed using the LSD test.
Normal distribution of parameters was checked by
means of the Shapiro-Wilk test. If data were not
normally distributed or the values of variance were
different, ANOVA with Kruskal-Wallis and Mann-
Whitney U test were used. All parameters were con-
sidered statistically significantly different if p < 0.05.
The statistical analysis of heart rate and hemody-
namic parameters was performed using Stat-
graphics 5.0 plus software.
Results
There were no significant differences among
groups of rats considering age and lipid profile
(Table I). The mean heart rate in the control group
was 441.47 ±5.60 min–1. In groups receiving sim-
vastatin at 1, 10 or 20 mg/kg bw during the 4-week
period, heart rate was comparable to the control
rats. No differences among groups receiving sim-
vastatin at 1, 10 or 20 mg/kg were observed, either.
Administration of 0.9% NaCl did not influence 
the heart rate as compared to the initial values
(99.55-101.21%). Metoprolol injection significantly
decreased heart rate in control rats (85.27%). In rats
receiving simvastatin at 1, 10 or 20 mg/kg bw for 
4 weeks, metoprolol decreased heart rate as com-
pared to rats receiving placebo (82.44% vs. 86.25%)
(Table II).
Mean blood pressure in control rats was 94.01
±4.34 mmHg and it was changed insignificantly
after 0.9% NaCl intraperitoneal injection (93.46
±4.43 mmHg). An insignificant influence of 0.9%
NaCl injection on the systolic (99.17%) and diastolic
blood pressure (99.08%) was observed as well. 
4-week administration of simvastatin at 1, 10 or 
20 mg/kg bw did not influence the mean systolic
and diastolic blood pressure in normotensive and
normocholesterolaemic rats. Intraperitoneal admin-
istration of 0.9% NaCl to rats receiving simvastatin
did not influence the mean systolic and diastolic
blood pressure, either. Intraperitoneal administra-
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tion of metoprolol to the control group and to rats
receiving simvastatin at all doses had no impact on
the blood pressure (Table III). 
Discussion
Pleiotropic effects of statins involve improve-
ment of endothelial function, stability of athero-
sclerotic plaques, decrease of oxidative stress and
inflammation, and inhibition of thrombogenic
response [3, 7, 9]. It has been reported that statins
increased the endothelial production of nitric oxide
(NO) and this effect was correlated with upregula-
tion of endothelial NO synthase expression [10]. It
was suggested that this effect might be intensified
by the simultaneous inhibition of G proteins and
reduction of endothelial NO synthase mRNA degra-
dation [11]. Anti-hypertensive statin activity may
result from drug impact on the decrease of vaso-
constrictor endothelin-1 level [12]. 3-Hydroxy-
3-methyl-glutaryl-CoA reductase inhibitors reduce
the production of reactive oxygen species, such 
as superoxide anion, and hydroxyl radicals, as
shown in experimental studies, and also this action
may contribute to vasodilatory effects of statins
[13]. Another possible mechanism of statin BP-low-
ering effect involves the downregulation of the
angiotensin II-type 1 receptor. The angiotensin 
II-type 1 receptor is overexpressed in hypercholes-
terolaemic patients, and it may be improved by
administration of statins, which also were shown
to markedly reduce the vasoconstrictor response
to angiotensin II infusion [14]. It was shown that
statins could improve systemic arterial compliance
in normolipidaemic patients with isolated systolic
hypertension via reduction of large artery stiffness
[15, 16].
By inhibiting HMG-CoA reductase, statins reduce
the production of important isoprenoids, i.e. farne-
syl pyrophosphate (FPP) and geranylgeranyl pyro  -
phosphate (GGPP). The isoprenylation process was
shown to influence signalling molecules, including
the monomeric GTPases of the Rho and Ras fami-
lies. However, isoprenylation of G protein γ subunit
(Gγ) was found to be essential for membrane
attachment of Gγ as well as Gβ [17, 18]. Statins, by
interfering with Gγ isoprenylation, could influence
membrane association and function of het-
erotrimeric G proteins [19-23]. The previous study
demonstrated that treatment of cardiac myocytes
with a statin reduced the cAMP level and induced
a significant increase in β-adrenergic receptor den-
sity [11]. The above mechanisms may lead to statins’
impact on the heart rate and blood pressure. 
Clinical observations in the UCSD Statin Study
and the Anglo-Scandinavian Cardiac Outcomes Tri-
al-Lipid Lowering Arm (ASCOT-LLA) suggest that
HMG-CoA reductase inhibitors might have some
BW [g] TC [mmol/l] LDL-C [mmol/l] HDL-C [mmol/l]T G  [mmol/l]
K_Na (9) 214 ±8.9 1.17 ±0.11 0.63 ±0.06 0.28 ±0.03 0.26 ±0.09
K_M (6) 210 ±14.0 1.27 ±0.20 0.76 ±0.09 0.24 ±0.09 0.27 ±0.06
S1_Na (6) 204 ±8.9 1.18 ±0.35 0.69 ±0.03 0.25 ±0.09 0.24 ±0.05
S1_M (6) 200 ±14.14 1.22 ±0.26 0.75 ±0.05 0.21 ±0.07 0.26 ±0.08
S10_Na (6) 202 ±11.2 1.25 ±0.01 0.75 ±0.10 0.25 ±0.03 0.25 ±0.09
S10_M (6) 210 ±14.0 1.21 ±0.07 0.68 ±0.07 0.24 ±0.05 0.29 ±0.05
S20_Na (5) 210 ±17.7 1.11 ±0.27 0.55 ±0.06 0.28 ±0.12 0.28 ±0.12
S20_M (7) 214 ±8.9 1.21 ±0.11 0.64 ±0.07 0.30 ±0.02 0.27 ±0.03
K_Na – control group receiving 0.9% NaCl injection, K_M – control group receiving metoprolol injection, S1_Na, S1_M – rats receiving 1 mg/kg
simvastatin and 0.9% NaCl or metoprolol injection, S10_Na, S10_M – rats receiving 10 mg/kg simvastatin and 0.9% NaCl or metoprolol injec-
tion, S20_Na, S20_M – rats receiving 20 mg/kg simvastatin and 0.9% NaCl or metoprolol injection, (n) – number of rats in group
Table I. Body weight (bw), total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), triglycerides (TG)
in rats (mean ± SD)
Metoprolol or 0.9% NaCl injection
Before After Difference [%]
K_Na (9) 441.47 ±5.60 445.01 ±4.53 100.84 ±0.65
K_M (6) 439.29 ±14.03 374.41 ±13.32 85.27 ±1.89t
S1_ Na (6) 443.41 ±13.45 448.74 ±13.78 101.21 ±0.72
S1_M (6) 429.37 ±14.46 356.97 ±7.48 83.41 ±2.66t
S10_Na (6) 419.40 ±10.63 418.48 ±9.93 99.81 ±0.77             
S10_M (6) 481.05 ±6.60 396.63 ±8.03 82.44 ±0.75t
S20_Na (5) 448.93 ±19.95 448.28 ±16.52 99.95 ±1.62
S20_M (7) 436.15 ±13.84 375.66 ±7.67 86.25 ±1.58t
K_Na – control group receiving 0.9% NaCl injection, K_M – control group
receiving metoprolol injection, S1_Na, S1_M – rats receiving 1 mg/kg
simvastatin and 0.9% NaCl or metoprolol injection, S10_Na, S10_M –
rats receiving 10 mg/kg simvastatin and 0.9% NaCl or metoprolol injec-
tion, S20_Na, S20_M – rats receiving 20 mg/kg simvastatin and 0.9%
NaCl or metoprolol injection, (n) – number of rats in group, ‘t’ – 
p < 0.05 t-par
Table II. Heart rate [min–1] before and after meto-
prolol or 0.9% NaCl intraperitoneal administration
(mean ± SE) in rats during 4-week administration of
simvastatin or placebo20 Arch Med Sci 1, February / 2012
blood-pressure-lowering properties in addition to
their effect on lipids [24, 25]. However, the CARE
study showed no significant reduction of BP with
statin therapy [26]. The different results in the CARE
and ASCOT studies may result from the degree of
LDL-C reduction achieved in the above trials. 
Another point is that a time- and dose-depen-
dent influence of statin on β1-adrenergic signalling
is observed. Atorvastatin reduced total G protein α
(s) subunit (Gαs) protein level concentrations
dependently and time-course experiments with 
1 μmol/l atorvastatin showed the first significant
effect after 24 h of treatment and a slightly larger
effect at 48 h [6]. Simvastatin administration in
patients undergoing cardiac surgery being treated
with metoprolol reversed upregulation of β1-adren-
ergic receptors [5]. It was connected with appease-
ment of the depressing metoprolol influence on
heart rate and blood pressure.
Our study demonstrates no impact of simvas-
tatin after four-week administration to rats on
blood pressure and heart rate after metoprolol
injection. Similar effects were observed in our
studies considering a 2-week period of statin
administration [7, 8]. Clinical observations of
reduction in heart rate and blood pressure after 
1-month concomitant administration of simvas-
tatin and metoprolol included study patients with
ischaemic heart disease or diabetes mellitus. The
inter-species differences could not be excluded.
The long-term concomitant administration of
statin with β1-blockers and lipid disturbances
could be important, considering the influence of
the drug-drug interaction on heart rate and
haemodynamic parameters. 
In conclusion, simvastatin administration during
a 4-week period in different doses did not influence
heart rate or blood pressure after metoprolol injec-
tion in normocholesterolaemic and normotensive
rats.
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